In this paper, we highlight the possibility of repositioning anti-diabetic drugs as a strategy for dementia therapy by analyzing clinical trials as well as integrating the molecular perspectives from various types of dementia through the insulin/IGF-1 signaling pathway. Here, IGF1 is linked to dementia.